2010
DOI: 10.1007/s11524-010-9451-7
|View full text |Cite
|
Sign up to set email alerts
|

Impact of Interim Methadone Maintenance on HIV Risk Behaviors

Abstract: The extent to which interim methadone (IM) without counseling reduces HIV risk behavior has not been reported. The AIDS Risk Assessment scale was administered at baseline and 4-month follow-up to 319 adult heroin-dependent participants randomly assigned to IM or waiting list. On an intent-to-treat basis, there was a significantly greater reduction in drug injection and unprotected sex while high from baseline to follow-up, favoring the IM condition. Remedying the shortage of methadone capacity through the expa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
20
0

Year Published

2011
2011
2021
2021

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 20 publications
(21 citation statements)
references
References 11 publications
1
20
0
Order By: Relevance
“…The benefits of interim treatment have been shown to persist through at least one year following enrollment into conventional treatment. Additional secondary analyses of data from these randomized trials have demonstrated the ability of interim treatment to reduce criminal (Schwartz et al, 2009) and HIV-risk (Wilson et al, 2010) behavior, as well as demonstrated its general cost-effectiveness (Schwartz et al, 2014). Taken together, when delays to treatment entry are unavoidable, the benefits of bridging these delays with daily medication and barebones clinical support are clear.…”
Section: Discussionmentioning
confidence: 99%
“…The benefits of interim treatment have been shown to persist through at least one year following enrollment into conventional treatment. Additional secondary analyses of data from these randomized trials have demonstrated the ability of interim treatment to reduce criminal (Schwartz et al, 2009) and HIV-risk (Wilson et al, 2010) behavior, as well as demonstrated its general cost-effectiveness (Schwartz et al, 2014). Taken together, when delays to treatment entry are unavoidable, the benefits of bridging these delays with daily medication and barebones clinical support are clear.…”
Section: Discussionmentioning
confidence: 99%
“…16, 17 Greater access to methadone treatment, for example, reduces HIV risk behaviour, and decreases HIV incidence rates overall. 18, 19 Researchers also found lower rates for discontinuing antiretroviral treatment among drug using populations receiving health and social services. 23 …”
Section: Introductionmentioning
confidence: 99%
“…17,18,20 In addition, HIV risk, and arrest appear to be reduced. 2122 Interim methadone can be scaled up relatively quickly to treat large numbers of patients in numerous programs and at a low cost (estimated at a few dollars per week/patient added to an existing program) that could be subsidized by low payments from the patients themselves. 23 Extant data from three clinical trials with methadone 37,53,54 indicate that early in treatment, patients receiving methadone alone fare as well as those who receive methadone with counseling.…”
Section: Discussionmentioning
confidence: 99%
“…These individuals were randomly assigned to receive interim methadone for up to 120 days, at which time they were transferred to standard methadone treatment, or remained on the usual waiting list. Participants in the interim group compared to those on the waiting list were found, over the course of two follow-up interviews at 4- and 10-months post-study entry, to have an increased likelihood of entering and remaining in standard methadone treatment and of reducing: opioid use 20 ; HIV risk behavior 21 ; criminal behavior 20 ; and, arrest. 22 This randomized trial suggested that interim methadone was an effective approach that suggested greater public health benefits and reductions in criminal activity when waiting lists were a significant barrier to treatment entry…”
Section: Introductionmentioning
confidence: 99%